Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer;L'association hormonothérapie néoadjuvante et irradiation externe dans les cancers de la prostate

Bulletin du Cancer

Volumn 93, Issue 11, 2006, Pages 1101-1105

  Bolla, Michel ^a   Artignan, Xavier ^a   Fourneret, Philippe ^a   Brochon, Danielle ^a   Ringeisen, François ^a   Descotes, Jean Luc ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Hormonal treatment; Prostate cancer; Radiotherapy

Indexed keywords

GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANDROGEN SUPPRESSION; ARTICLE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; PELVIS LYMPH NODE; PROGNOSIS; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 33845919356     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0158     Document Type: Article

References (23)

1. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Standford University. NCI Monogr 1988; 7: 47-60.
2. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology 2001; 8: 1049-59.
3. Huggins C, Hodges CV. Studies on prostate cancer I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
4. Holtzman M, Carlton CE, Scardino PT. The frequency and morbidity of local recurrence after definitive radiotherapy for stage T3 prostate cancer. J Urol 1991; 146: 1578-82.
5. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy : sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 1067-70.
6. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumours to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997; 38: 1071-7.
7. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase > III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15-23.
8. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52.
9. Denhmam JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasmian Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-50.
10. Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advacnced prostate cancer (an EORTC study); a phase III randomized trial. Lancet 2002; 360: 103-6.
11. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserilin. N Engl J Med 1997; 337: 295-300.
12. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-46.
13. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90.
14. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with D1/pathologic nodepositive adenocarcinoma of the prostate : updated results based on national prospective randomized trial Radiation Therapy Oncology Group. J Clin Oncol 2005; 23: 800-7.
15. Grantors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for non metastatic prostate cancer with or without pelvic lymph node involvement: a prospective ran-domized study. J Urol 1998; 159: 2030-4.
16. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med 1999; 341: 1781-8.
17. Roach M, Desilvio M, Lawion C, et al. Phase III trial comparing wholepelvis versus prostate only radiotherapy and neodjuvant versus adjuvant combined androgen suppression : Radiation Therapy Oncology Group 9413. Int J Radiat Oncol BM Phys 2003; 21: 1904-11.
18. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long term androgen adjuvant deprivation after neodajuvant hormonal cytoreduction and radiotherapy in locally adva7nced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8.
19. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 2004 292: 821-7.
20. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomi-zed radiotherapy dose-escalation study comparing 70 with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-11.
21. Bolla M. EORTC 22961. Long term adjuvant hormonal treatment with LHRH analogue vs no further treatment in locally advanced prostatic carcinoma treated by external irradiation and a six months combined androgne blockade. A phase III study. EORTC Data Center, 1996.
22. Oudard S, Medioni J, Scotte F, Banu E. Actualité dans le cancer de la prostate. Bull Cancer 2005; 92: 865-73.
23. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 : 1502-12.